prohibited list comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
=== Lungs === Fibrothorax Pulmonary fibrosis Cystic fibrosis Idiopathic pulmonary fibrosis (idiopathic meaning 'of unknown cause') Radiation-induced lung injury (following radiation therapies commonly used to treat cancer)
The fertile material in the thorium fuel cycle has an atomic weight of 232, while the fertile material in the uranium fuel cycle has an atomic weight of 238. That mass difference means that thorium-232 requires six more neutron capture events per nucleus before the transuranic elements can be produced. In addition to this simple mass difference, the reactor gets two chances to fission the nuclei as the mass increases: First as the effective fuel nuclei U233, and as it absorbs two more neutrons, again as the fuel nuclei U235. Breeders aim to produce more fissile material than they consume. Burners aim to consume actinides by incorporating them into the core fuel and not adding a breeding blanket.
==== Dominance by tech giants ==== The commercial AI scene is dominated by Big Tech companies such as Alphabet Inc., Amazon, Apple Inc., Meta Platforms, and Microsoft. Some of these companies already own the vast majority of existing cloud infrastructure and computing power from data centres, allowing them to entrench further in the marketplace. For most of 2025-2026, AI-related companies have also dominated stock market returns. According to a July 2024 report from S&P Global, investors had started questioning whether the enormous spending on AI infrastructure and data centers would generate sufficient profits, leading to increased volatility in technology and semiconductor stocks and to concerns about a potential AI bubble. In a 2025 Economic Policy article, economists Anton Korinek and Jai Vipra described some AI related market sectors as highly concentrated.
Sources: en.wikipedia.org
One important use of American kestrels is in falconry. It is often considered a beginner's bird, though the careful weight control needed to maintain the kestrel's desire to aggressively hunt takes skill. Falconers experienced in extracting the best performance the species is capable of, report they are highly reliable on the normal game of sparrows and starlings. More aggressive individuals are sometimes capable of capturing prey up to approximately twice their own body weight, allowing the occasional capture of true game birds such as quail and dove. However, most falconers interested in the reliable taking of such game do prefer larger falcons or hawks. The advantage the American kestrel offers the experienced falconer is its suitability to simple and urban falconry not requiring large tracts of land or the use of hunting dogs. This form of falconry is sometimes referred to as "micro-falconry" or "micro-hawking". The other small raptor species commonly used in micro-falconry are the merlin, the sharp-shinned hawk (the smallest Accipiter), and the European kestrel (a true kestrel). Hawking with the American kestrel requires adapting to the strengths and weaknesses of the bird. It is a tiny falcon, and even for its size, it is less muscular than other small falcons such as the athletic and swift merlin. It is more adapted to ambush hunting and short chases than to the longer aerial chases larger falcons often adopt. Used within its limits, it is effective.
C-reactive protein (CRP) is an annular (ring-shaped) pentameric protein found in blood plasma, whose circulating concentration rises in response to inflammation. It is an acute-phase protein of hepatic origin that increases following interleukin-6 secretion by macrophages and T cells. Its physiological role is to bind to lysophosphatidylcholine expressed on the surface of dead or dying cells (and some types of bacteria) in order to activate the complement system via C1q. CRP is synthesized by the liver in response to factors released by macrophages, T cells and fat cells (adipocytes). It is a member of the pentraxin family of proteins. It is not related to C-peptide (insulin) or protein C (blood coagulation). C-reactive protein was the first pattern recognition receptor (PRR) to be identified.
=== Thorium-234 === 234Th is an isotope of thorium whose nuclei contain 144 neutrons. 234Th has a half-life of 24.11 days; it emits a beta particle, transmuting into protactinium-234 with a decay energy around 0.27 MeV. Uranium-238 almost always produces isotope of thorium on decay (although in rare cases it undergoes spontaneous fission, and even more rarely double beta decay).
== Genomics == The gene is located on long arm of chromosome 11 (11q13) between base pairs 64,570,985 and 64,578,765. It has 10 exons and encodes a 610-amino acid protein. Over 1300 mutations have been reported to date (2010). The majority (>70%) of these are predicted to lead to truncated forms are scattered throughout the gene. Four - c.249_252delGTCT (deletion at codons 83-84), c.1546_1547insC (insertion at codon 516), c.1378C>T (Arg460Ter) and c.628_631delACAG (deletion at codons 210-211) have been reported to occur in 4.5%, 2.7%, 2.6% and 2.5% of families.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.